Table 2.
- Results Summary
| Investigated attributes | Medicine group | ||
|---|---|---|---|
| Filgrastim (G-CSF) |
Epoetin alfa (EPO) |
Somatropin (HGH) |
|
| Medicine being listed | |||
| Not listed | 27 (18%) | 31 (21%) | 20 (14%) |
| Listed as formulary | 115 (79%) | 107 (73%) | 120 (82%) |
| Listed as non-formulary | 4 (3%) | 8 (6%) | 6 (4%) |
| Total | 146 | 146 | 146 |
| Clear prescription restrictions | |||
| Yes | 78 (66%) | 77 (67%) | 84 (67%) |
| No | 41 (34%) | 38 (33%) | 42 (33%) |
| Total | 119 | 115 | 126 |
| Listing approach | |||
| INN name | 58 (49%) | 44 (38%) | 64 (51%) |
| Brand names | 49 (41%) | 60 (52%) | 59 (47%) |
| Mixed listing | 12 (10%) | 11 (10%) | 3 (2%) |
| Total | 119 | 115 | 126 |
| Listed brands | |||
| Both | 36 (59%) | 21 (30%) | 25 (40%) |
| R-BMP only | 11 (18%) | 48 (68%) | 4 (7%) |
| BSPs only | 14 (23%) | 2 (3%) | 33 (53%) |
| Total | 61 | 71 | 62 |
| Preferred type | |||
| R-BMP | 10 (16%) | 52 (73%) | 29 (47%) |
| BSPs | 30 (49%) | 4 (6%) | 7 (11%) |
| Unclear | 21 (34%) | 15 (21%) | 26 (42%) |
| Total | 61 | 71 | 62 |
| Specified brand of choice | |||
| Yes | 13 (21%) | 4 (6%) | 9 (15%) |
| No | 48 (79%) | 67 (94%) | 53 (85%) |
| Total | 61 | 71 | 62 |
| Special population considerationsa | |||
| Yes | 3 (5%) | 8 (11%) | 10 (16%) |
| No | 58 (95%) | 63 (89%) | 52 (84%) |
| Total | 61 | 71 | 62 |
| Special indication considerations | |||
| Yes | 9 (15%) | 7 (10%) | 0 (0%) |
| No | 52 (85%) | 64 (90%) | 62 (100%) |
| Total | 61 | 71 | 62 |
BSP biosimilar medicinal product; INN international non-proprietary name (molecular name); R-BMP reference biological medicinal product
aFactors related to patient population or indication that might affect prescriber brand/product of choice